North America Cervical Cancer Screening Market: By Test Type (Pap Smear Tests, HPV Tests, LBC Tests, and Others), Country (USA, and Canada) and Forecast to 2030

Purchase Option

$ 3100
$ 4600
$ 6900

North America Cervical Cancer Screening Market size was valued at USD 459.3 million in 2023 and is expected to reach USD 465.8 million by 2030, growing at a CAGR of 0.2% from 2024 to 2030. In terms of cervical cancer screening, North America leads the industry by a wide margin. This dominance is fueled by a potent mix of factors that encourage widespread screening and continuous improvement in the healthcare landscape. In addition, technological innovation plays a crucial role in driving growth and efficiency in the North American cervical cancer screening market. The introduction of HPV testing, a more sensitive and specific screening tool, has led to earlier detection and improved prevention strategies. Also, the liquid-based cytology (LBC) technique improves the quality of pap smears by preserving more diagnostic cells, leading to increased accuracy and a reduction in false negatives.

Moreover, automation in sample processing and analysis allows for faster turnaround times and increased screening capacity, optimizing workflows and patient experience. Furthermore, the North American healthcare system is constantly evolving to be more patient-centered. The emergence of home-based HPV testing options empowers women who might face barriers to traditional clinical settings by offering increased convenience and privacy. Also, the simultaneous testing for both pap smears and HPV can streamline the screening process and provide more comprehensive results, reducing the need for repeat tests. The integration of telehealth services allows for remote consultations with healthcare providers regarding screening options and results, improving accessibility and convenience. However, ensuring equitable access to screening services for minority communities and women in rural areas remains a crucial concern.

North America Cervical Cancer Screening Market Key Developments:
  • In November 2023, Abbott received the US FDA approval for its Alinity high risk (HR) HPV assay. This will add the assay to their molecular diagnostics portfolio. The assay can be used alongside the Pap test.
  • In March 2023, The BD Onclarity™ HPV Assay was incorporated into the NHS Cervical cancer screening program, which can be viewed as a big win for the company. The assay allows for at-home collection of vaginal swab samples making it more convenient, easy, accessible, and potentially less uncomfortable for women compared to clinician-taken cervical samples.

North America Cervical Cancer Screening Market Dynamics

North America's strong foundation in cervical cancer screening rests upon a well-established culture of preventive healthcare. Extensive public health initiatives have fostered a strong understanding of the importance of regular screening. Women are more likely to be knowledgeable about cervical cancer and its prevention strategies. In addition, public health messages and educational programs emphasize the benefits of early detection through regular screening, encouraging women to prioritize their health. Moreover, the structured screening programs provide a robust framework that facilitates access and participation. Clear guidelines are established regarding recommended screening intervals and preferred testing methods. This ensures consistency across healthcare providers. Furthermore, funding and resources are allocated to support screening programs, which allows for improved access to services, particularly for underserved populations. Also, targeted outreach programs are implemented to educate women about available screening options and address potential barriers to participation.

North America Cervical Cancer Screening Market Segmentation

By Test Type
  • Pap Smear Tests
  • HPV Tests
  • LBC Tests
  • Others
By Country
  • USA
  • Canada

Frequently Asked Questions

The North America cervical cancer screening market is projected to expand at a CAGR of 0.16% during the forecast period.

The leading players in the North America cervical cancer screening market are Abbott Laboratories, Hologic Inc., Qiagen N.V., Becton, Dickinson and Company (BD), F. Hoffmann-La Roche Ltd. (Roche), Quest Diagnostics Incorporated, CooperSurgical Inc., and Femasys, Inc.

Historic years considered for the market study are 2019 to 2022, 2023 is considered as the base year for market estimation and the forecast presented from 2024 to 2030.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.
1.Executive Summary
2. North America Cervical Cancer Screening Market Introduction 
2.1. North America Cervical Cancer Screening Market  - Taxonomy
2.2. North America Cervical Cancer Screening Market  - Definitions
2.2.1.Test Type 
2.2.2.Region
3. North America Cervical Cancer Screening Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. North America Cervical Cancer Screening Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. North America Cervical Cancer Screening Market  By Test Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Pap Smear Tests
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. HPV Tests
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. LBC Tests
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6. North America Cervical Cancer Screening Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. United States of America (USA)
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Canada
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.United States of America (USA) Cervical Cancer Screening Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Test Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
7.1.1.Pap Smear Tests
7.1.2.HPV Tests
7.1.3.LBC Tests
7.1.4.Others
8.Canada Cervical Cancer Screening Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Test Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Pap Smear Tests
8.1.2.HPV Tests
8.1.3.LBC Tests
8.1.4.Others
9. Competition Landscape
9.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
9.2.1.Abbott Laboratories
9.2.2.Hologic Inc.
9.2.3.Qiagen N.V.
9.2.4.Becton, Dickinson and Company (BD)
9.2.5.Hoffmann-La Roche Ltd. (Roche)
9.2.6.Quest Diagnostics Incorporated
9.2.7.CooperSurgical Inc.
9.2.8.Femasys, Inc.
10. Research Methodology 
11. Appendix and Abbreviations 
  • Abbott Laboratories
  • Hologic Inc.
  • Qiagen N.V.
  • Becton, Dickinson and Company (BD)
  • Hoffmann-La Roche Ltd. (Roche)
  • Quest Diagnostics Incorporated
  • CooperSurgical Inc.
  • Femasys, Inc.

Adjacent Markets